Dr. Palumbo on CASTOR Trial Results in Multiple Myeloma
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Antonio Palumbo, MD, chief, Myeloma Unit, Department of Oncology, Section of Hematology, University of Torino, Italy, discusses the phase III results of the CASTOR trial, which was a randomized controlled study examining the efficacy of daratumumab (Darzalex), bortezomib (Velcade), and dexamethasone versus bortezomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
In this study, the primary endpoint was progression-free survival. Results showed that the addition of daratumumab reduced the risk of disease progression by 61%, Palumbo says.
Additionally, there were major increases in response rates in patients who received the triplet regimen. The complete response rate was doubled from 9% to 19%, while the rate of very good partial response was doubled from 29% to 59%. This demonstrates that the 3-drug therapy should be considered the standard of care for these patients, he explains.
<<<
